Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response heterogeneity

Anamorelin effectively improved LBM and appetite/QOL domains in pancreatic cancer, particularly in patients with low BMI. However, hyperglycemia-especially in those with impaired insulin secretion-requires careful monitoring. Baseline BMI and insulin secretion capacity should be evaluated before initiating therapy, and these findings provide preliminary insight into treatment response heterogeneity in pancreatic cancer cachexia.